Explore
Validate
Learn500-P105-1MG
antibody from Invitrogen Antibodies
Targeting: CXCL3
CINC-2b, GRO3, GROg, MIP-2b, SCYB3
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations
- Western blot [2]
- ELISA [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 500-P105-1MG - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CXCL3 Polyclonal Antibody, PeproTech®
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- AA Sequence of recombinant protein: ASVVTELRCQ CLQTLQGIHL KNIQSVNVRS PGPHCAQTEV IATLKNGKKA CLNPASPMVQ KIIEKILNKG STN.
- Concentration
- 0.1-1.0 mg/mL
Submitted references NAP-2 Secreted by Human NK Cells Can Stimulate Mesenchymal Stem/Stromal Cell Recruitment.
The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.
Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis.
Almeida CR, Caires HR, Vasconcelos DP, Barbosa MA
Stem cell reports 2016 Apr 12;6(4):466-473
Stem cell reports 2016 Apr 12;6(4):466-473
The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma.
Mestas J, Burdick MD, Reckamp K, Pantuck A, Figlin RA, Strieter RM
Journal of immunology (Baltimore, Md. : 1950) 2005 Oct 15;175(8):5351-7
Journal of immunology (Baltimore, Md. : 1950) 2005 Oct 15;175(8):5351-7
Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis.
White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):853-60
Clinical cancer research : an official journal of the American Association for Cancer Research 2003 Feb;9(2):853-60
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human GRO-gamma (CXCL3) by Western Blot analysis CXCL3 Polyclonal Antibody (Product # 500-P105-1MG) can be used at a concentration of 0.1-0.2 µg/mL. When used in conjunction with compatible secondary reagents, the detection limit for Recombinant Human GRO-gamma (CXCL3) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western Blot: To detect Human GRO-gamma (CXCL3) by Western Blot analysis CXCL3 Polyclonal Antibody (Product # 500-P105-1MG) can be used at a concentration of 0.1-0.2 µg/mL. When used in conjunction with compatible secondary reagents, the detection limit for Recombinant Human GRO-gamma (CXCL3) is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Sandwich ELISA: To detect Human GRO-gamma (CXCL3) by sandwich ELISA (using 100 µL/well antibody solution) a concentration of 0.5-2.0 µg/mL of CXCL3 Polyclonal Antibody (Product # 500-P105-1MG) is required. This antigen affinity purified antibody, in conjunction with PeproTech CXCL3 Polyclonal Antibody, Biotin (Product # 500-P105BT-1MG) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human GRO-gamma (CXCL3).
